Protease inhibitor candidate substance…Intravenous injection system under development
Pfizer, an American pharmaceutical company, has started a clinical trial of an oral antiviral drug for the treatment of COVID-19.
On the 23rd (local time), Pfizer conducted a single phase 1 clinical trial in the United States in healthy adults to evaluate the safety and tolerability of an oral antiviral drug candidate for SARS-CoV-2, the virus that causes COVID-19. It was announced that multiple ascending doses were being administered after the ascending dose was completed.
Pfizer’s oral antiviral candidate PF-07321332 is a SARS-CoV2-3CL protease inhibitor. In vitro experiments showed strong antiviral activity against SARS-CoV-2 and other coronaviruses, and it was observed that it may be effective against not only SARS-CoV-2 but also other coronaviruses.
Protease inhibitors bind to viral enzymes to prevent the virus from replicating in cells, and are proven to be effective in treating viral pathogens such as HIV (human immunodeficiency virus) and hepatitis C virus.
Currently commercially available viral protease-targeted therapeutics are generally not related to toxicity, so this kind of substance can present a therapeutic agent with good tolerability to COVID-19.
This phase 1 clinical trial is a randomized, double-blind, open-source, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of PF-07321332 in healthy adults.
The initiation of the clinical trial is supported by a preclinical study in which the antiviral activity of the first SARS-CoV-2 therapeutic agent in this class, designed to inhibit SARS-CoV-2 virus replication, has been observed.
Pfizer will release the structure and preclinical data of PF-07321332 at the Spring American Chemical Society on the 6th of next month.
Dr. Michael Dolsten, Pfizer’s Chief Scientific Officer, said, “To combat the corona 19 pandemic, both vaccine-based prevention and targeted treatment for people infected with the virus are necessary.” “It will be important to ensure access to treatment options now and even after the pandemic, given the continued global impact of the company.”
“We designed PF-07321332 as an oral treatment that can be prescribed at the first sign of infection without the need for hospitalization or intensive care,” he said. In development,” he introduced.
“The two treatments can create a complete end-to-end treatment paradigm that complements vaccination if the disease continues to occur.”
Pfizer is evaluating PF-07304814, an intravenous COVID-19 treatment candidate, in hospitalized patients in a phase 1b multi-dose trial.
Copyright © Unauthorized reproduction and redistribution of medical news is prohibited.